Typhoid (enteric) Fever is caused by Salmonella Typhi afflicting 11-21 million people and killing 128,000-161,000 people worldwide each year, as reported by the World Health Organization. (https://www.who.int/immunization/diseases/typhoid/en)
Matrivax has developed Typhax, a Typhoid Fever vaccine candidate that utilizes its proprietary PCMV technology.
A Phase 1 clinical trial demonstrated that Typhax exhibited a favorable safety and immunogenicity profile when compared to the commercial vaccine, Typhim Vi.
The seroconversion rate in Typhax recipients was higher than in Typhim Vi recipients, at 1/10th the dose contained in the commercial vaccine.